Published in Antiviral Res on March 01, 2011
The curious case of arenavirus entry, and its inhibition. Viruses (2012) 1.11
Functional interferon system is required for clearance of lassa virus. J Virol (2012) 1.05
Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever. Antiviral Res (2012) 0.95
A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J Infect Dis (2013) 0.94
Animal models, prophylaxis, and therapeutics for arenavirus infections. Viruses (2012) 0.93
Dissection of the role of the stable signal peptide of the arenavirus envelope glycoprotein in membrane fusion. J Virol (2012) 0.91
Progress in the experimental therapy of severe arenaviral infections. Future Microbiol (2011) 0.90
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res (2011) 0.88
The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep (2015) 0.85
Molecular mechanism of arenavirus assembly and budding. Viruses (2012) 0.83
Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein. J Virol (2016) 0.75
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis (1987) 5.27
Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg (1970) 4.96
The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4.21
A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis (1987) 3.51
The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A (2001) 3.43
Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ (1995) 3.21
Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg (1974) 2.95
Clinical virology of Lassa fever in hospitalized patients. J Infect Dis (1987) 2.94
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis (1980) 2.38
In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother (2007) 2.21
Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis (2001) 2.07
Imported Lassa fever--New Jersey, 2004. MMWR Morb Mortal Wkly Rep (2004) 2.03
Acute sensorineural deafness in Lassa fever. JAMA (1990) 2.02
Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg (1973) 1.91
Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J Virol (1992) 1.84
Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol (1987) 1.83
Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ (1975) 1.83
The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol (2001) 1.80
Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J Virol (2006) 1.71
Protein-protein interactions in lymphocytic choriomeningitis virus. Virology (1991) 1.68
Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis (1989) 1.65
The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill (2009) 1.63
Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med (2006) 1.60
Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. Otolaryngol Head Neck Surg (1992) 1.58
Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology (1990) 1.58
Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. Antiviral Res (2007) 1.50
Pathogenesis of Lassa virus infection in guinea pigs. Infect Immun (1982) 1.47
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis (2001) 1.45
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues. J Virol (2007) 1.41
A fatal case of Lassa fever in London, January 2009. Euro Surveill (2009) 1.40
Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol (1987) 1.40
Kinetics and pH dependence of acid-induced structural changes in the lymphocytic choriomeningitis virus glycoprotein complex. Virology (1995) 1.37
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One (2008) 1.32
Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis (1984) 1.30
DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology (1999) 1.29
Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem (2008) 1.29
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol (1986) 1.22
Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex. J Virol (2007) 1.19
Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein. Virology (2005) 1.17
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
Lassa fever vaccine. Expert Rev Vaccines (2004) 1.08
Clinical features of Lassa fever in Liberia. Rev Infect Dis (1989) 1.08
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Lassa fever: the first confirmed case imported into Canada. Can Dis Wkly Rep (1989) 1.05
Lassa fever imported to England. Commun Dis Rep CDR Wkly (2000) 1.04
Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J Med Virol (1983) 1.01
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr (2005) 0.98
Haemolysis as an interference factor in clinical chemistry. J Clin Chem Clin Biochem (1986) 0.93
Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus. Antimicrob Agents Chemother (2007) 0.92
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther (2007) 0.92
Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother (1986) 0.92
Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med Microbiol Immunol (1986) 0.88
Standardization of a plaque assay for Lassa virus. J Med Virol (1987) 0.84
Arenavirus infection in the guinea pig model: antiviral therapy with recombinant interferon-alpha, the immunomodulator CL246,738 and ribavirin. Antiviral Res (1989) 0.84
Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy. J Chemother (2008) 0.77
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther (2005) 0.77
Rats, fever and sudden deafness in Sierra Leone. Trop Doct (1992) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Comparative genome sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element evolution. Genome Res (2005) 8.38
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci (2009) 3.77
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J Clin Invest (2007) 3.32
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A (2004) 3.03
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res (2007) 2.47
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
The role of insulin receptor substrate 2 in hypothalamic and beta cell function. J Clin Invest (2005) 2.40
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Oxidative stress and neurotoxicity. Chem Res Toxicol (2007) 2.12
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Neural circuit involved in idiopathic infantile nystagmus syndrome based on FMRI. J Pediatr Ophthalmol Strabismus (2011) 2.02
Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev (2003) 1.97
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.92
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis (2002) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Alzheimer's disease: the two-hit hypothesis. Lancet Neurol (2004) 1.81
Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol (2011) 1.80
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol (2009) 1.75
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J (2006) 1.69
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem (2009) 1.67
Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta (2009) 1.66
Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol (2003) 1.66
Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem (2002) 1.65
Alzheimer disease. Dis Mon (2010) 1.64
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem (2005) 1.61
The vaccinia virus I7L gene product is the core protein proteinase. J Virol (2002) 1.61
Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem (2007) 1.61
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab (2009) 1.59
The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals (2003) 1.56
Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta (2006) 1.56
A new model of oxidative stress in rat pups. Neonatology (2008) 1.55
Impaired regulation of synaptic strength in hippocampal neurons from GluR1-deficient mice. J Physiol (2003) 1.55
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
Chitin-like polysaccharides in Alzheimer's disease brains. Curr Alzheimer Res (2005) 1.51
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta (2009) 1.49
Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci (2004) 1.49
Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheimers Dis (2002) 1.47
Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J (2002) 1.47
Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A (2003) 1.46
4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol (2005) 1.46
Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology (2010) 1.46
Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med (2008) 1.45
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol (2008) 1.45
Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate. J Virol (2004) 1.44
Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med (2002) 1.44
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem (2009) 1.43
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis (2009) 1.42
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol Psychiatry (2007) 1.39
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum Mol Genet (2011) 1.38
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res (2002) 1.37
Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci (2007) 1.37
Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS One (2008) 1.37